Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
25%
Ph phase_1
2
25%
Ph phase_2
4
50%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 24 (50.0%)
Phase 32 (25.0%)

Trials by Status

unknown113%
active_not_recruiting113%
completed563%
not_yet_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
not_yet_recruitingphase_3

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

NCT07379333
active_not_recruitingphase_3

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

NCT06174779
completedphase_2

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172
completedphase_2

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
completedphase_2

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02081118
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07379333Phase 3

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Not Yet Recruiting
NCT06174779Phase 3

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Active Not Recruiting
NCT02057172Phase 2

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Completed
NCT01452451Phase 2

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Completed
NCT02081118Phase 2

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Completed
NCT02075281Phase 2

Effect of LAPS-Exendin on Body Weight in Obese Population

Completed
NCT02059564Phase 1

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Unknown
NCT01093729Phase 1

A Study of HM11260C in Healthy Male Subject

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8